Effectiveness of Lecanemab on Alzheimer’s Disease

• Published in: Precision nanomedicine 2024-01, Vol.7 (1)
• Main Authors: Thomas, Flen John, Sarguroh Khan, Mohammad Aamir Qayyum, Khan, Ramlah Atif, Patel, Sarthak Vasantkumar
• Format: Article
• Language: English
• ISSN: 2639-9431; 2639-9431
• DOI: 10.33218/001c.92098

Alzheimer’s disease (AD) is a global public health crisis with a significant impact on individuals, families, and societies. Monoclonal antibodies have emerged as a potential disease-modifying therapy targeting amyloid-β (Aβ), a hallmark of AD pathology. This study offers a comprehensive overview of the efficacy and safety of lecanemab, a monoclonal antibody, focusing on its binding properties and clinical trial results. Lecanemab’s unique binding profile, with a strong affinity for toxic Aβ protofibrils, sets it apart from other monoclonal antibodies. Clinical trials have shown promising results, including reductions in amyloid burden, improvements in cognitive measures, and a reduction in the rate of cognitive decline. However, limitations such as small sample sizes, short-term follow-up, and the exclusion of certain patient groups must be considered. While lecanemab shows potential in slowing the progression of AD, a more extensive study is required to provide robust evidence of its efficacy, especially in diverse patient populations. Adverse effects and long-term safety also warrant further investigation. The results of this study have the potential to inform clinical guidelines and benefit healthcare professionals, caregivers, and researchers in their efforts to improve the treatment of AD. This review is a crucial step in addressing the growing challenge of AD and enhancing the well-being of affected individuals and their families.